<DOC>
	<DOCNO>NCT00002436</DOCNO>
	<brief_summary>To evaluate safety efficacy low high dos lamivudine ( 3TC ) combination zidovudine ( AZT ) zalcitabine ( dideoxycytidine ; ddC ) combination AZT . PER 02/27/95 AMENDMENT : To evaluate efficacy safety blind open-label combination therapy .</brief_summary>
	<brief_title>The Safety Effectiveness Three Anti-HIV Drug Combinations HIV-Infected Patients Who Have Taken AZT</brief_title>
	<detailed_description>Patients randomize one three treatment arm : low-dose 3TC plus AZT , high-dose 3TC plus AZT , ddC plus AZT . Treatment continue 32 week , possible extension 52 week . PER 02/27/95 AMENDMENT : Patients may continue therapy AZT low-dose 3TC open-label basis . Open-label therapy continue follow-up every 8 week intolerable toxicity occur study terminates .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV positivity . CD4 count 100300 cells/mm3 . Prior AZT therapy 24 week currently AZT . Exclusion Criteria Patients follow prior condition exclude : History intolerance AZT . History grade 2 bad peripheral neuropathy . Prior Medication : Excluded : Any prior antiretroviral therapy AZT . Required : Concomitant AZT therapy . Required : At least 24 week prior AZT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1994</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>